Sunbird Bio - About the company
Sunbird Bio is a series B company based in Singapore, founded in 2020 by Huilin Shao, Nicholas Ho and Carine Lim. It operates as a Developer of blood-based diagnostic tests for neurological disorders. Sunbird Bio has raised $14M in funding from investors like Polaris Partners, EDBI and Lilly. The company has 482 active competitors, including 171 funded and 83 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Annexon.
Company Details
Developer of blood-based diagnostic tests for neurological disorders. The company’s technology detects proteins associated with neurological disorders. These tests support diagnosis and treatment of diseases, such as Alzheimer's, Parkinson's, and ALS. The technology aims to provide researchers and clinicians with diagnostic information for differential diagnoses.
- Website
- www.sunbirdbio.com/
- Email ID
- *****@sunbirdbio.com
- Registered Address
- COLLYER QUAY, Singapore, 49317
Key Metrics
Founded Year
2020
Location
Stage
Series B
Total Funding
$14M in 1 round
Latest Funding Round
Investors
Ranked
25th among 482 active competitors
Employee Count
19 as on May 31, 2026
Investment & Acquisitions
Similar Companies
Legal entities associated with Sunbird Bio
Sunbird Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
SUNBIRD BIO PTE. LTD. UEN: 202011554D , Singapore, Active | Apr 15, 2020 | - | - |
Sign up to download Sunbird Bio's company profile
Sunbird Bio's funding and investors
Sunbird Bio has raised a total funding of $14M over 1 round. Its latest funding round was a Series B round on Oct 16, 2024 for $*****. 5 investors participated in its latest round. Sunbird Bio has 8 institutional investors and 2 angel investors.
Here is the list of recent funding rounds of Sunbird Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 16, 2024 | 6649504 | Series B | 2908604 | 4351176 | 6641006 | 1481653 |
Access funding benchmarks and valuations. Sign up today!View details of Sunbird Bio's funding rounds and investors
Sunbird Bio's founders and board of directors
Founder? Claim ProfileHere are the details of Sunbird Bio's key team members:
- Huilin Shao: Co-Founder of Sunbird Bio. They serve on the board of 1 company.
- Nicholas Ho: Co-Founder of Sunbird Bio.
- Carine Lim: Co-Founder of Sunbird Bio.
Sunbird Bio's Board of Directors
Sunbird Bio's board has 1 active member. Huilin Shao is part of team.Here is the list of Sunbird Bio's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 6y 4m | |
cvpmtyb | Independent board member | - | Past | 2y 2m |
View details of Sunbird Bio's Founder profiles and Board Members
Sunbird Bio's employee count trend
Sunbird Bio has 19 employees as of May 26. Here is Sunbird Bio's employee count trend over the years:
Uncover Sunbird Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sunbird Bio's Competitors and alternates
Top competitors of Sunbird Bio include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Sunbird Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 70/100 | |
3rd | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
4th | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
5th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 65/100 | |
6th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
7th | Alchemab 2019, London (United Kingdom), Series A | Developer of antibody therapeutics for treating oncology and neurodegenerative conditions | $149M | 65/100 | |
8th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Developer of small molecule inhibitors targeting specific disease associated enzymes | $192M | 64/100 | |
9th | US World Meds 2001, Louisville (United States), Series B | Developer of therapeutics for the treatment of multiple diseases | $149M | 64/100 | |
10th | Developer of imaging capsules for colorectal cancer screening | $9.88M | 64/100 | ||
25th |  Sunbird Bio 2020, Singapore, Series B | Developer of blood-based diagnostic tests for neurological disorders | $14M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Sunbird Bio's competitors? Click here to see the top ones
Sunbird Bio's Investments and acquisitions
Sunbird Bio has acquired Glympse Bio. Sunbird Bio has not made any investments as of now.Reports related to Sunbird Bio
Here is the latest report on Sunbird Bio's sector:
News related to Sunbird Bio
Filter this listMedia has covered Sunbird Bio for 1 event in last 1 year, It was about company updates.
•
Sunbird Bio Presents New Clinical Data Supporting the Accuracy of its Blood-Based Alpha-Synuclein Assay for Parkinson’s Disease DetectionBusiness Wire•Dec 04, 2025•Sunbird Bio
•
Sunbird Bio Appoints Richard Batrla, M.D., Ph.D., MBA as Chief Medical OfficerSunbird Bio•Aug 01, 2025•Sunbird Bio
•
Sunbird Bio Appoints Vijay Parthasarathy, Ph.D., MBA, as Chief Product and Strategy OfficerBusiness Wire•Mar 11, 2025•Sunbird Bio, Exact Sciences
•
Sunbird Bio Appoints Richard Batrla, M.D., Ph.D., MBA as Chief Medical OfficerBusiness Wire•Jan 08, 2025•Sunbird Bio
•
Sunbird Bio Raises Additional $14 Million to Advance Broadest Blood-Based Diagnostic Platform in Alzheimer’s Disease and Other Neurological Disordersintelligence360•Nov 04, 2024•Sunbird Bio, S32, Polaris Partners, Clavystbio and 2 others
•
•
Sunbird Bio Raises Additional $14 Million to Advance Broadest Blood-Based Diagnostic Platform in Alzheimer’s Disease and Other Neurological DisordersBusiness Wire•Oct 16, 2024•Sunbird Bio, Lilly, South32, Polaris Partners and 5 others
•
Sunbird Bio Raises Additional $14 Million to Advance Broadest Blood-Based Diagnostic Platform in Alzheimer’s Disease and Other Neurological DisordersSunbird Bio•Oct 16, 2024•Sunbird Bio, Lilly, Singapore Economic Development Board, EDBI and 3 others
•
Sunbird Bio Presents Latest Data Reinforcing Significance of Blood-Based Tau Biomarkers in the Accurate Diagnosis of Alzheimer’s DiseaseBusiness Wire•Jul 28, 2024•Sunbird Bio
•
Sunbird Bio merges with Glympse Bio to accelerate development of protein-based diagnostic technologiesBioSpectrum Asia•Aug 13, 2023•Sunbird Bio, TinyURL
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Sunbird Bio
Explore our recently published companies
- April-e Real Estate - Rincon De La Victoria based, Unfunded company
- Accretive and Innovative Consulting - Unfunded company
- 40/60 - UX - France based, 2016 founded, Unfunded company
- Mon Terrassa - Spain based, 2016 founded, Unfunded company
- Delaire - Spain based, Unfunded company
- DataHunt - Unfunded company
